Krsnaa Diagnostics reports record profit in Q2 FY26 as Rajasthan project gains traction and ACR nod boosts global credibility

Krsnaa Diagnostics Limited (BSE: 543328; NSE: KRSNAA), one of India’s fastest-growing diagnostic service providers, reported its highest-ever quarterly profit for Q2 FY26. The performance was bolstered by expanding patient volumes, a maturing public-private partnership footprint, and landmark global accreditations. For the quarter ended September 30, 2025, the company reported a 22 percent year-on-year jump in net profit to ₹239 million, along with a corresponding 18 percent rise in EBITDA to ₹602 million. Revenue rose to ₹2,060 million, marking 11 percent growth over the previous year.

For the first half of FY26, consolidated revenue reached ₹3,990 million, up 12 percent from ₹3,566 million in H1 FY25. Net profit rose to ₹445 million, up 19 percent year-on-year. Diluted earnings per share stood at ₹13.50 for H1 FY26 compared to ₹11.38 a year ago. EBITDA margins improved to 28 percent, while profit after tax margins came in at 11 percent, highlighting the company’s improving operating leverage and disciplined cost execution.

How did Krsnaa Diagnostics deliver record profits and margin expansion in Q2 FY26?

Krsnaa Diagnostics’ record performance in Q2 FY26 was largely driven by scale benefits, robust patient throughput, and network expansion into underpenetrated regions. Managing Director Yash Mutha credited the company’s consistent execution and high-visibility PPP model for delivering profitable and sustainable growth. EBITDA rose to ₹1,126 million for H1 FY26, marking an 18 percent increase over the year-ago period, with consistent 28 percent margin strength.

The company operates a nationwide diagnostic platform designed around its public-private partnership model, which integrates radiology and pathology services into state-run hospitals and clinics. This model not only ensures steady patient volumes and long-term contracts but also enables deep reach into Tier-II and Tier-III locations where access to quality diagnostics remains limited. Krsnaa Diagnostics now operates more than 4,000 centers across 15 states and three Union Territories, with a technology backbone that supports real-time teleradiology, cloud-based PACS workflows, and remote reporting from certified radiologists and pathologists worldwide.

What is the status of the Rajasthan PPP project and how could it shape Krsnaa’s future revenue trajectory?

One of the most closely tracked milestones for Krsnaa Diagnostics is the ongoing execution of its Rajasthan PPP project, billed as the largest diagnostic public-private partnership in India. According to the company, the rollout remains on schedule, with multiple laboratories expected to go live in the coming months. Revenue contribution is anticipated to begin from the fourth quarter of FY26, with a full-year impact projected in FY27.

The Rajasthan diagnostic network is expected to provide comprehensive radiology and pathology coverage through a decentralized hub-and-spoke model. This project is seen as a template for how scalable, government-backed healthcare infrastructure can be delivered cost-effectively in India. Institutional stakeholders have been closely monitoring this rollout as a litmus test of both operational scalability and contract-backed revenue stability. Given Krsnaa Diagnostics’ track record with other state-led projects, the company is expected to leverage learnings from earlier PPPs to execute the Rajasthan model at scale.

How do international accreditations enhance Krsnaa Diagnostics’ brand and patient trust?

A major milestone during the quarter was Krsnaa Diagnostics’ receipt of accreditation from the American College of Radiology (ACR), marking the first-ever ACR certification granted outside the United States. In addition to the ACR recognition, the company continues to hold College of American Pathologists (CAP) accreditation for one of its government diagnostic locations, another rarity in India’s public healthcare infrastructure.

Executive Director Pallavi Bhatevara stated that these dual global accreditations represent a breakthrough for clinical quality and compliance standards in India. These endorsements, typically reserved for elite institutions in developed healthcare markets, reaffirm Krsnaa Diagnostics’ commitment to delivering internationally benchmarked diagnostics at scale. She further noted that these certifications will enhance patient confidence, drive volume growth, and improve institutional partnerships, all of which are vital for long-term expansion.

In the diagnostics industry, trust plays a pivotal role in driving recurring business. Global accreditations significantly increase referral volumes from clinicians and hospitals while establishing brand leadership in tenders and partnerships. The company was also recently recognized as “India’s Most Trusted Integrated Diagnostic Brand” at the Big FM – Big Impact Awards in Vietnam, underscoring growing cross-border brand recall and stakeholder confidence.

How are institutional investors interpreting Krsnaa’s FY26 performance amid broader healthcare sector dynamics?

Krsnaa Diagnostics’ Q2 FY26 performance has resonated positively with institutional investors. Analysts believe that the company’s consistent margin expansion and high-quality revenue growth, particularly from its asset-light PPP operations, make it an attractive long-term healthcare infrastructure play. The improving earnings profile and volume expansion are seen as validation of the company’s operating model, especially in an environment where many diagnostics peers are seeing moderation in post-pandemic volumes.

Institutional sentiment also remains anchored to the company’s disciplined working capital management. Despite a reported receivable cycle exceeding 150 days linked to new Reserve Bank of India-aligned central payment mechanisms, the company emphasized that it has not recorded any bad debts since inception. This clean book, combined with government-backed contracts, helps mitigate credit risk and strengthens its investment case.

As investors increasingly seek exposure to public-health-focused businesses with long-term visibility, Krsnaa Diagnostics stands out for its ability to convert operational efficiency into consistent free cash flows. The Rajasthan rollout, ACR/CAP accreditations, and ongoing state partnerships are expected to serve as catalysts in upcoming quarters.

What does the long-term growth roadmap look like for Krsnaa Diagnostics?

Krsnaa Diagnostics is building a high-visibility growth engine centered around three pillars: nationwide coverage through PPPs, global quality compliance, and technology-driven diagnostics delivery. The company’s proprietary PACS systems, cloud-based diagnostic workflows, and centralized reading capabilities allow it to scale without overextending fixed costs.

Over the next 12 to 24 months, management is expected to focus on optimizing receivables, accelerating project-level execution, and driving incremental revenue from new labs under the Rajasthan and other state partnerships. With a mission to deliver accessible and affordable diagnostics under the philosophy of “Let’s Do Good,” Krsnaa is positioning itself not just as a volume player but as a brand that can anchor the next generation of Indian healthcare infrastructure.

The broader backdrop also works in Krsnaa’s favor. India’s healthcare diagnostics market is undergoing rapid formalization, supported by Ayushman Bharat Digital Mission, state-level insurance programs, and increased allocation to public health infrastructure. In this context, Krsnaa Diagnostics has emerged as a high-trust, technology-first operator with the scale and credibility to shape national diagnostic delivery models.

What are the key takeaways from Krsnaa Diagnostics’ Q2 FY26 earnings and operational update?

• Krsnaa Diagnostics Limited reported its highest-ever quarterly profit of ₹239 million in Q2 FY26, up 22 percent year-on-year.
• EBITDA rose 18 percent to ₹602 million for the quarter, with EBITDA margin expanding to 29 percent from 27 percent a year ago.
• Revenue from operations increased 11 percent to ₹2,060 million in Q2 FY26 and 12 percent to ₹3,990 million in H1 FY26.
• The company reported a 23 percent year-on-year rise in diluted earnings per share to ₹7.25 for the quarter.
• The Rajasthan public-private partnership diagnostic rollout is progressing on schedule, with revenue contribution expected from Q4 FY26 and full-year impact in FY27.
• Krsnaa Diagnostics became the first Indian diagnostic player to receive accreditation from the American College of Radiology (ACR), in addition to holding College of American Pathologists (CAP) certification.
• These dual global accreditations strengthen patient trust, enhance clinical referrals, and increase brand credibility across public and private healthcare networks.
• The receivable cycle extended beyond 150 days due to alignment with new Reserve Bank of India-linked government payment mechanisms, but the company has reported zero bad debts since inception.
• Analysts and institutional investors are viewing the margin expansion and disciplined execution favorably, reinforcing the attractiveness of the company’s PPP-based, asset-light diagnostic model.
• Krsnaa Diagnostics continues to expand its nationwide footprint with over 4,000 diagnostic centers across 15 states and three Union Territories, supported by advanced teleradiology and cloud-based platforms.